Root-knot Nematode Resistance Gene Patent Grant

USPTO granted patent US12588644B2 to Rijk Zwaan Zaadteelt En Zaadhandel B.V. covering a nucleic acid encoding the MeR1 protein that confers resistance to root-knot nematode in Solanaceae plants. The patent includes 18 claims covering the gene sequences, amino acid sequences, and methods of using the resistance gene in plant breeding. The inventors are Raoul Jacobus Johannes Maria Frijters, Jonathan Kalisvaart, and Adriaan Verhage.

Otoferlin Dual Vector Systems for Treating Sensorineural Hearing Loss

The USPTO granted Regeneron Pharmaceuticals Patent US12589168B2 for compositions and methods treating sensorineural hearing loss using otoferlin (OTOF) dual vector gene therapy systems. The patent covers a two-vector approach delivering N-terminal and C-terminal portions of OTOF isoform 5 to restore gene function in patients with OTOF mutations. Application No. 17733744 was filed April 29, 2022.

177Lu peptide targets uPAR receptor for colorectal cancer treatment

USPTO granted patent US12589171B2 to TRT INNOVATIONS APS covering a 177-Lu labeled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) for treatment of cancers with high uPAR expression, particularly colorectal cancer. The patent includes 9 claims and lists inventors Andreas Kjaer, Morten Persson, and Michael Ploug.

CD80 Extracellular Domain Fc Fusion Proteins for Treating PD-L1 Negative Tumors

The USPTO granted Patent US12589132B2 to Five Prime Therapeutics, Inc. covering fusion proteins combining the CD80 extracellular domain with the Fc domain of IgG1 for treating PD-L1 negative tumors. The patent includes 22 claims and names Susannah D. Barbee, Thomas Brennan, and Barbara Sennino as inventors. This grant establishes exclusive rights for the assignee in this therapeutic application.

Verily Patent for CGM Pattern Discovery in Diabetes Management

The USPTO granted Verily Life Sciences LLC Patent US12588838B1 for a diabetes management platform that analyzes continuous glucose monitoring (CGM) data to identify patterns indicative of similar behaviors or circumstances. The platform applies dynamic time warping algorithms to multiple data series to generate distance measures and discover patterns. The patent, with 20 claims, covers CPC classifications in G16H (Healthcare Informatics) and A61B (Measuring/Diagnosing).

Trolox-peptide conjugate and use thereof

USPTO issued Patent Grant US12589064B2 to Caregen Co., Ltd. on March 31, 2026, covering a Trolox-peptide conjugate for hair loss prevention. The patented compound inhibits 5α-reductase activity, prevents papilla cell and keratinocyte death, promotes cell growth, and provides antioxidant effects. The patent contains 9 claims and names Yong Ji Chung, Eun Mi Kim, Eung Ji Lee, and Min Woong Kim as inventors.

Process for the production of levetiracetam

USPTO granted Patent US12590059B2 to Suzhou BrightHope Pharmatech Co., Ltd. for a process to produce levetiracetam via crystallization in aqueous solution, resulting in a product containing no residual organic solvent. The patent lists 4 inventors (Songzhou Hu, Lijun Deng, Wen Yu, Zhen Song) and contains 13 claims under classification C07D 207/27.

Levorphanol prodrugs and processes for making and using them

The USPTO granted Patent US12590065B2 to Zevra Therapeutics, Inc. covering novel levorphanol prodrug compositions formed by chemically conjugating oxoacids, polyethylene glycols, or vitamin compounds to levorphanol. The patent includes claims to the compositions and methods of making and using them.

Fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and use thereof

USPTO granted Patent US12590066B2 to Korea Institute of Science and Technology for novel fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds. The patent includes 20 claims and names inventors Ae Nim Pae, Yun Kyung Kim, Sang Min Lim, Sungsu Lim, Haeun Lee, Woo Seung Son, and Hye Yeon Lee. The compounds have potential pharmaceutical applications.

Decision Letter - Docket FRA-2009-0078

The Federal Railroad Administration posted a decision letter in docket FRA-2009-0078 on March 30, 2026. The document resolves an administrative proceeding before the FRA, with the specific subject matter determined by the underlying complaint or petition filed in the 2009-docketed matter. Further details require review of the attached decision document.